A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy

Trial Profile

A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Talacotuzumab (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 25 Jul 2018 to 25 Jan 2018.
    • 13 Sep 2017 Planned primary completion date changed from 2 Jul 2018 to 25 Jan 2018.
    • 18 Aug 2017 Planned End Date changed from 2 Jul 2018 to 25 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top